Verbatim response from ChatGPT
Short answer
- No — commercially available compounded “GLP‑1 drops” or home‑made tablets are not a reliable substitute for approved injectable GLP‑1 drugs. The only FDA‑approved oral GLP‑1 is oral semaglutide (brand name Rybelsus). Injectables (e.g., semaglutide as Ozempic/Wegovy, tirzepatide as Mounjaro/Zepbound) have the strongest, most consistent evidence for blood‑sugar control and weight loss.
Why compounded oral drops/tablets are problematic
- Peptides are fragile: GLP‑1 receptor agonists are peptide drugs that are rapidly broken down in the stomach and gut unless specially formulated (Rybelsus uses an absorption enhancer, SNAC). Simple drops or tablets made by compounding pharmacies usually don’t reproduce that technology, so oral absorption and effect are unpredictable or negligible.
- Quality and dose uncertainty: Compounded products are not FDA‑approved. Their potency, purity, sterility, and shelf life can vary. Several clinics and online vendors sell “drops” or “sublingual” forms with no rigorous testing or clinical data.
- Safety risks: Wrong dosing, contamination, or counterfeit ingredients can cause harm. You’d also miss appropriate medical monitoring for side effects (nausea, pancreatitis risk, gallbladder issues, thyroid concerns) or drug interactions.
- Legal/regulatory issues: Some compounding of widely available, FDA‑approved drugs is disallowed or discouraged; regulators have flagged unapproved or fraudulent GLP‑1 products in the market.
What is shown to work
- Rybelsus (oral semaglutide) — FDA‑approved for type 2 diabetes; it’s formulated for oral absorption and has clinical trial data. It generally produces less weight loss than the weekly injectable semaglutide products at doses used for obesity (Wegovy) or some tirzepatide trials.
- Injectables (examples: Wegovy/Ozempic for semaglutide; Mounjaro/Zepbound for tirzepatide) — established dosing, predictable absorption, large clinical trials showing glycemic and weight‑loss benefits. For many patients seeking substantial weight loss, injectables are more effective.
If you’re offered a compounded oral GLP‑1 — what to ask
- Ask for a Certificate of Analysis (COA) showing the API identity and potency.
- Ask the pharmacy to document the source of the active ingredient (is it pharmaceutical‑grade API?).
- Ask how sterility, stability, and storage are validated and what testing is done (microbiological, endotoxin).
- Confirm the pharmacy’s licensing and whether they follow USP compounding standards.
- Ask your prescriber about evidence for the specific formulation and whether they’ll monitor you medically.
My recommendation
- Prefer FDA‑approved options under a clinician’s care. If you need an oral option, discuss Rybelsus with your provider. If you need maximal weight‑loss effect or stronger glycemic control, discuss injectable options (semaglutide or tirzepatide) with an experienced prescriber.
- Avoid unverified online “drops” or compounded tablets unless you and your clinician have independently verified the compounding pharmacy’s testing and documentation and accept the risks.
If you want, tell me what specific product or vendor you’re seeing and I can help evaluate the risks and questions to ask.